CESSATECH Aktie

 

Selected top 5 summarized questions from investors focusing on the top-line results of Study 0202 and US launch plans 1.Data from Study 0202 – any potential impact for later commercialization or EMA approval process? · We believe the top-line data shared, is really good – and most importantly it fits very well with the predicted data from Study 0208. An overall pain reduction of 75% is considered very good.  · There is not much data in acute pain on children, but two larger studies (+400 children), had a reduction in pain of -64% and -60% (the last being an IV administration study)....

· Welcome to new member of the Executive Management team, Martin Juhl · Acknowledgment of his great contribution and importance for the future development of Cessatech On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of Directors announces the promotion of Chief Scientific Officers (CSO) Martin Juhl as a member of the Executive Management team, effective today. The appointment is a direct recognition of Martin's significant impact on the company. This expansion of the leadership team strengthens Cessatech's capacity to execute on its mission to develop vital new...

· As announced on 28 May 2025, the Board of directors in Cessatech exercised an authorization to increase the share capital through a directed issue of shares. · A total of 1,151,343 shares have now been registered at the Danish Business Authority, resulting in an increase in Cessatech's share capital of nominally DKK 230,268.60. THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH ANNOUNCEMENT, DISTRIBUTION...

· As announced on 28 May 2025, Cessatech launched a directed share offering to certain institutional and professional investors through an accelerated bookbuilding process. · The Board of directors in Cessatech has exercised an authorization to increase the share capital by issuing 1,163,123 shares to a limited number of semi-institutional and professional investors.   · Shares will be issued at a subscription price DKK 12.72 per share. · Aggregate gross proceeds from the issue will amount to approximately DKK 14.8 million and Cessatech intends to use the net proceeds for general...

· A directed share issue of minimum DKK 10 million to certain institutional and professional investors through an accelerated bookbuilding process will begin immediately.  · Net proceeds from the directed issue are expected to be used for accelerating U.S. commercialization following finalization of U.S. manufacturing setup during 2025. On 28 of May, Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) announces its intention to carry out a directed issue of minimum DKK 10 million at market price to institutional and other professional investors with the purpose of...

· The primary endpoint of responder analysis, of pain relief (pain score ≤4/10), was met and reported by 55% of patients after 15 minutes and by 89% after 30 minutes.  · Overall pain reduction was 75% after 30 minutes, and 86% after 60 minutes.   · No drug related unexpected adverse effects, and they were all transient and of mild to moderate intensity. Copenhagen, 28 May - 17.15 On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from its Paediatric Study 0202, an open-label trial in the development program of CT001 an intranasal, needle-free...

The Company has advanced well with its planned activities · Positive CT001 MDR assessment  · Finalization of Paediatric Safety Study 0202 · US manufacturing and launch finalization still in process · EMA submission planning process Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2025. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.  First quarter financial results 2025 (1 January – 31 March): · Net Revenue was KDKK 1....

· 150 paediatric patients have been recruited in Study 0202 as planned · Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in children · Top-line results are expected within the next 3-6 weeks · The EMA submission process can now be initiated, for submission later this year On 30 April – Cessatech A/S (“Cessatech” or “the Company”) announces that it has completed the patient recruitment of its final study Paediatric Study 0202 in the development program of CT001. Study 0202 is the final required clinical study that will...

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Friday 28 March 2025 at 09:00 (CET) at the Company's address Strandvejen 60, 2900 Hellerup. The agenda for the general meeting was as follows: 1. ELECTION OF CHAIRMAN OF THE MEETING 1. Mikkel Rostock-Jensen was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the annual general meeting and announced that the annual general meeting had been duly convened and was legal and competent in terms of all items on...

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 28 March 2025. The shareholders of Cessatech A/S The board of directors hereby convenes the annual general meeting of Cessatech to be held on Thursday 28 March 2025 at 9.00 (CET) at the Company's address Strandvejen 60, 2900 Hellerup. The agenda for the general meeting is as follows: 1. ELECTION OF CHAIRMAN OF THE MEETING 2. REPORT ON THE ACTIVITIES OF THE COMPANY IN THE PAST FINANCIAL YEAR 3. PRESENTATION OF THE ANNUAL REPORT WITH AUDITORS' REPORT FOR ADOPTION 4. RESOLUTION...

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2024, which also includes the fourth quarter of 2024 financial reporting. The annual report is attached as a pdf. The report is also available on Cessatech's website www.cessatech.com under 'Fillings & Reports'. Full year 2024 for the period 1 January - 31 December (Q4'2024 results in brackets): · Net revenue was KDKK 2.486 (-870) · Operating result was KDKK -19.053 (-8.667) · Net result was KDKK -14.670 (-7.216) · Cash at bank end of the period was KDKK 12.373 (12.373) ·...

· Great progress from the year 2024, including the commercialization agreement for CT001. · The US launch is still pending and our main focus for the coming period. · In 2025 we will work hard for new partnerships, new opportunities and get CT002 moving. On 23 December – Cessatech A/S (“Cessatech” or “the Company”) gives an update on the major milestones for the coming year. We are very pleased with the progress Cessatech has made during 2024, and this is truly the result of an incredible team-effort and partnership collaborations. During 2024 we closed the agreement with Proveca...

The Company has advanced well with its planned activities · Commercial partnership agreement with Proveca Ltd · Good progress with Paediatric Safety Study 0202 · Loan Facility Agreement extended to the year 2026 · US manufacturing and launch finalization in process Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2024. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.  Third quarter financial results 2024 (1 July - 30...

· 75 paediatric patients have now been recruited in Study 0202 · Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in children · CT001 is a nasal spray for the treatment of acute pain in children On 16 October – Cessatech A/S (“Cessatech” or “the Company”) announces that it has reached the halfway point for patient recruitment of its final study Paediatric Study 0202 in the development program of 0202. Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in 150 children....

Selected top 10 investor questions On 2 September – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based on the positive feedback and questions received from investors following the agreement with Proveca on CT001. 1. How many potential partners have you had dialogue with for Europe? A: We have had several discussions with 6-7 companies, and the process has taken longer than expected. It was not until our meetings with Proveca that we felt confident about finding the best match for our objectives and aspirations. 2. What are your...

· Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.   · Proveca has been granted a non-exclusive option to license Cessatech's CT002 program. · Proveca is a global pharmaceutical company specialising in the development and licensing of medicines to address the unmet medical needs in children. Proveca is based in Manchester, England. On 26 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company...

The Company has advanced well with its planned activities · First patient dosed in Paediatric Safety Study 0202 · Superior simulated pain efficacy in children with CT001 · New member of the Board of Directors, Anders Dyhr D-Toft · US launch finalization and final approvals still ongoing... Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2024. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.  Second quarter financial results...

· The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 million to DKK 10 million and the maturity extended until April 2026. · The new loan facility agreement provides Cessatech increased financial flexibility and support for the upcoming US launch of CT001. · To date Cessatech has not drawn on the facility and the Loan Facility Agreement can potentially be converted into shares on market conditions. On 12 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has extended the...

· The US launch is almost there · More paediatric data to be presented at IASP 2024, World Congress on Pain · Commercial partnerships for Europe is also a key priority On 2 August 2024 Cessatech A/S ("Cessatech" or the "Company") has given an update for its key priorities for the remaing part of this year. The  short update includes the Company's key priorities and some of the most important events for the remaining part of 2024. The US launch is almost there Timing of first sale - Both teams have been very busy preparing for the launch under the Early Access Program in the US -...

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant a new incentive warrants to existing and new employees, to the CEO and the Board of Directors. The reason for the new warrant program is to retain and incentivize the employees, the Board of Directors and the CEO by offering a long-term ownership engagement, which will contribute to an alignment of interests between the warrant holders and the shareholders and promote long-term commitment to the Company's development. Background and final terms On 26 July 2024 it was decided to grant 250,000 warrants...